©2024 Stanford Medicine
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
Not Recruiting
Trial ID: NCT01805141
Purpose
The investigators hope to learn whether perfusion CT is a useful way to assess primary
cervical tumor microenvironment and whether there is a relationship between pretreatment
perfusion CT measurements and primary cervical tumor size, lymph node involvement (as
assessed by standard of care pretreatment fludeoxyglucose Positron emission tomography/CT
(FDG-PET/CT)), and treatment response (as assessed by standard of care 3-month post-therapy
FDG-PET/CT).
Official Title
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
Stanford Investigator(s)
Elizabeth Kidd
Associate Professor of Radiation Oncology (Radiation Therapy)
Aya Kamaya, MD
Professor of Radiology (Body Imaging)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Eligibility
Inclusion criteria:
- >18 years old
- with biopsy-proven squamous, adenocarcinoma or adenosquamous cervical cancer
- no history of prior pelvic radiation and should be able to receive chemoradiation
- non-pregnant women who have not previously undergone a hysterectomy, as that would
have removed the cervix.
- able to give informed consent
Exclusion criteria:
- Subjects whose tumors are not FDG avid on the pre-therapy PET.
- Allergy or inability to receive iodinated CT contrast
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Melissa Usoz
650-723-8843